News

Cytiva Expands Bengaluru Facility to Strengthen India’s Biopharma Process Development Ecosystem

New 30,000 sq. ft. Fast Trak™ center signals growing demand for localized biologics manufacturing and validation expertise.

• By PharmaNews Live Desk
• Bengaluru
• Feb 26, 2026

News

Cytiva, a Danaher-owned life sciences company, has expanded its Fast Trak™ process development and validation services facility in Bengaluru, marking a significant addition to India’s growing bioprocessing infrastructure.

The approximately 30,000 square foot center is designed to support biopharmaceutical companies across India and the Asia-Pacific region as they work to shorten development cycles, manage scale-up risks and meet increasingly complex regulatory requirements. The move comes as India positions itself to grow its bioeconomy to USD 300 billion by 2030, with biologics and advanced therapies forming a central pillar of that ambition.

Integrated Development and Validation Capabilities

The expanded facility consolidates upstream and downstream process development, optimization, scale-up and validation services within a single location. It also includes hands-on training modules aimed at strengthening technical capacity among industry professionals.

The center supports multiple therapeutic modalities, including monoclonal antibodies (mAbs), plasmid DNA (pDNA) and mRNA platforms, recombinant proteins, and viral vectors — areas that are witnessing accelerated investment globally, particularly in cell and gene therapies and next-generation vaccines.

Industry experts note that such integrated facilities can reduce reliance on overseas contract development support, allowing Indian biopharma firms to access global-standard infrastructure domestically while retaining tighter control over intellectual property and timelines.

Meeting Rising Demand for Domestic Biologics Manufacturing

The expansion reflects broader global shifts toward strengthening domestic manufacturing of biologics. Cytiva’s 2025 Biopharma Index indicates that more than half of global biopharma executives expect a significant rise in domestic biologics production over the next three years.

In India, this trend is reinforced by growing demand for biosimilars, specialty biologics and emerging modalities. Companies are increasingly seeking localized expertise capable of meeting international quality and compliance benchmarks.

The Bengaluru facility operates within a GLP-compliant biosafety level 2 (BSL-2) environment and supports single-use bioreactor scale-up up to 200 liters. It also enables production of toxicity batch material for preclinical development. An ISO-certified validation laboratory provides testing and documentation services, including validation of sterilizing-grade filters and single-use systems — key components in biologics manufacturing.

Strengthening India’s Bioprocessing Ecosystem

India’s biopharma sector has evolved rapidly over the past decade, moving beyond generics to advanced biologics and complex therapies. However, access to high-quality scale-up infrastructure and validation services has remained a bottleneck for several emerging biotech companies.

By expanding its Fast Trak™ operations in Bengaluru, Cytiva is adding capacity at a time when Indian firms are scaling research pipelines and targeting global markets. The facility is positioned to support early-stage development through to pre-commercial manufacturing, helping companies improve yield, enhance product consistency and reduce manufacturing risk.

As biologics manufacturing becomes more technology-intensive and regulatory scrutiny tightens globally, the availability of integrated process development infrastructure within India could play a crucial role in accelerating commercialization timelines.

The expansion underscores a broader shift in the life sciences industry — one where speed, flexibility and regulatory readiness are becoming as critical as innovation itself.